Wells Fargo & Company Neurocrine Biosciences Inc Transaction History
Wells Fargo & Company
- $434 Billion
- Q3 2024
A detailed history of Wells Fargo & Company transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Wells Fargo & Company holds 260,415 shares of NBIX stock, worth $30.6 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
260,415
Previous 234,969
10.83%
Holding current value
$30.6 Million
Previous $32.3 Million
7.32%
% of portfolio
0.01%
Previous 0.01%
Shares
19 transactions
Others Institutions Holding NBIX
# of Institutions
623Shares Held
94.2MCall Options Held
632KPut Options Held
621K-
Black Rock Inc. New York, NY14.2MShares$1.67 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA10MShares$1.18 Billion0.02% of portfolio
-
State Street Corp Boston, MA5.15MShares$606 Million0.02% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny2.57MShares$303 Million0.47% of portfolio
-
Bellevue Group Ag Kuesnacht, V81.86MShares$219 Million3.62% of portfolio
About NEUROCRINE BIOSCIENCES INC
- Ticker NBIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 95,639,296
- Market Cap $11.2B
- Description
- Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...